Dana-Farber Cancer Institute: Neoplasms trials

The registry lists 42 Neoplasms studies with Dana-Farber Cancer Institute as lead sponsor. 9 are open to participants now and 12 have results posted.

Phase 1 13Phase 2 12No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pedi-STAR: Surface Target Antibody-drug Conjugate (ADC) Antigen Expression in Relapsed/Refractory Pediatric Solid and CNS TumorsNot yet recruitingNCT07793994Not applicable
• BRIDGE-SIC Efficacy TrialRecruitingNCT07735442Not applicable
• The DISCOVER StudyNot yet recruitingNCT07390643Not applicable
• On-Trac: An Online Intervention for Cancer Survivors Managing AnxietyRecruitingNCT07305740Not applicable
• ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRsRecruitingNCT07232043Not applicable
• Proof-of-Concept Testing of the Cardiovascular Health Equity Through Food (CHEF) Intervention in Childhood Cancer SurvivorsRecruitingNCT06609473Not applicable
• PediRISE FeasibilityRecruitingNCT06283251Not applicable
• Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
• Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6RecruitingNCT03310879Phase 2
• Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)CompletedNCT05358951Not applicableResults posted
• Preventative Skin Care for Children Undergoing Targeted CNS Tumor TherapyCompletedNCT04479514Phase 2Results posted
• Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results posted
• Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT03717480Phase 2Results posted
• The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced CancerCompletedNCT03668223Not applicableResults posted
• Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms TumorsTerminatedNCT02581384Phase 1/2Results posted
• Patient-Centered Care for the Older Adult With Hematologic MalignancyCompletedNCT02359838Not applicableResults posted
• Image-guided Cryoablation of Head, Neck and Spine TumorsCompletedNCT02085941Not applicableResults posted
• Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsCompletedNCT01466036Phase 2Results posted
• AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedNCT01024387Phase 2Results posted
• Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian MalignanciesCompletedNCT00856180Phase 2Results posted
• Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian TumorsCompletedNCT00520013Phase 2Results posted
• Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness CommunicationActive, not recruitingNCT07147023Not applicable
• MyeloGen: Germline Testing for Predisposition to Myeloid MalignanciesWithdrawnNCT06543511Not applicable
• PediCARE Health Equity Intervention in High-Risk NeuroblastomaWithdrawnNCT06335745Not applicable
• A Novel Intervention for Patients With CancerCompletedNCT05643027Not applicable
• Mindfulness-Music Intervention for Adolescents and Young Adults With CancerCompletedNCT03709225Not applicable
• Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric CancerCompletedNCT03654716Phase 1
• Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1
• BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified TumorsWithdrawnNCT02656849Phase 2
• Parental Decision-Making for Children With Relapsed NeuroblastomaActive, not recruitingNCT02282735
• iCAT for Recurrent/Refractory/HR Solid TumorsCompletedNCT01853345
• Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT00942682Phase 1
• Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine TumorsCompletedNCT00804336Phase 1
• Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic MalignanciesCompletedNCT00675831Phase 1
• Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic TransplantCompletedNCT00476177Phase 1
• Trial of PTK787/ZK 222584 Plus PaclitaxelTerminatedNCT00358163Phase 1
• Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor MalignanciesCompletedNCT00251407Phase 1
• Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor MalignanciesCompletedNCT00215501Phase 1
• Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With CancerCompletedNCT00165100Not applicable
• Talotrexin in Treating Patients With Advanced or Recurrent Solid TumorsCompletedNCT00098514Phase 1
• Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain TumorCompletedNCT00069940Phase 1
• High-dose ICE With AmifostineCompletedNCT00003657Phase 2